CymaBay Therapeutics (CBAY) Stock

CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.

Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billion.

CymaBay (NASDAQ: CBAY ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ: GILD ). That deal has Gilead Sciences agreeing to acquire CymaBay for $4.3 billion.

CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead-CymaBay agreement The said deal values CymaBay at $32.50 per share.

Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.

Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for a total deal equity value of $4.3 billion. CymaBay's lead asset is seladelpar, an investigational treatment for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.

CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

The leading drug candidate in the biotech's pipeline scored another win. Seladelpar's existing Breakthrough Therapy Designation was expanded by the FDA.

CymaBay Therapeutics stock is continuing a slide that began last week. The pullback came on the heels of the biotech's dilution-causing stock and warrant offering.